CA125和CA153联合检测对乳腺癌的诊治价值

目的 探讨肿瘤标志物CA125和CA153对乳腺癌诊断和疗效监测的价值.方法 采用电化学发光法对乳腺癌170例、乳腺良性疾病102例及健康体检者153例的血清进行CA125和CA153联合检测,并对乳腺癌80例术后第3天、1周、2周和1个月的CA125和CA153的水平进行监测.应用ROC曲线对各指标进行分析.结果 乳腺癌组CA153、CA125均明显高于乳腺良性疾病组与正常对照组（P ＜0.05）；CA153、CA125两项联合检测,其灵敏度为79.41％、准确度为87.53％、阴性预测值为87.13％,与单项指标比较差异均有统计学意义（P＜0.05）.CA153、CA125两项肿瘤标志物单独检测时,CA153的ROC曲线下面积（AUC）为0.823较CA125大；两项联合指标的AUC达0.876,大于各单项肿瘤标志物（P＜0.05）.结论 CA153、CA125是乳腺癌的肿瘤相关性标志物,CA153对于乳腺癌的诊断价值更大.两项指标联合检测优于单一的肿瘤标志物检测,可提高诊断乳腺癌的正确性.CA153、CA125亦可用于乳腺癌患者术后疗效的观察.

Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer

Objective To investigate the value of combined tumor markers CA125 and CA153 in diagnosing and effect moni- toring in breast cancer. Methods Using electro-chemoluminescent immunoassay （ECLIA） method to determine and analyze the level of CA125 and CA153 in 170 patients with breast cancer, 102 patients with benign breast disease ,and 153 normal individuals. The levels of CA125 and CA153 were detected in 80 breast cancer patients with post-operation time 3 day, 1 week ,2 week and 1 month respective- ly. The results were analyzed by ROC curve. Results The serum levels of CA153 and CA125 in the patients with breast cancer were higher than those of normal individuals and patients with benign breast disease （ P 〈 0.05 ）. The sensitivity, accuracy and negative pre- dictive rate combined two tumor markers of serum CA153 and CA125 were 79.41% ,87.53% and 87.13% ,which had prognostic sig- nificance compared with CA153 and CA125 alone （P 〈 0.05 ）. The AUC of CA153 was 0. 823 and it was higher than that of CA125. The AUC of two combined tumor markers of CA153 and CA125 was 0. 876 and it was higher than any AUC of CA153 or CA125 alone （ P 〈 0.05 ）. With pos-operation time passed by, the level of CA125 and CA153 declined gradually （ P 〈 0.05 ）. Conclusion CA153 and CA125 were the correlative tumor markers of breast cancer,and CA153 was more helpful in diagnosing breast cancer. Detection of combining CA125 with CA153 was better than single tumor marker, which can raise the accuracy of diagnosing patients with breast cancer or monitoring their therapy effect post-operation.